Get to know our clinical trials

Phase I/II, open-label study of safety, tolerability, pharmacokinetics and antitumor activity of repotrectinib in pediatric and young adult patients with advanced or metastatic tumors with ALK, ROS1 or NTRK1-3 rearrangements (CARE).

Dr. Elena Panizo Curriculum
Specialist Pediatrics Department
Navarre headquarters
Madrid headquarters
Cancer Center
Pediatric Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE I/II, OPEN-LABEL STUDY OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND ANTITUMOR ACTIVITY OF REPOTRECTINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH ADVANCED OR METASTATIC TUMORS WITH ALK, ROS1 OR NTRK1-3 REARRANGEMENTS (CARE).
  • Code EudraCT: 2019-003055-11
  • Protocol number: TPX-0005-07
  • Promoter: Turning Point Therapeutics, Inc
  • Molecule/Drug: repotrectinib

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION